The impact of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance
10.3760/cma.j.issn.1000-6680.2012.04.007
- VernacularTitle:二甲双胍对胰岛素抵抗的基因1型慢性丙型肝炎患者抗病毒疗效的影响
- Author:
Jianwu YU
;
Lijie SUN
;
Peng KANG
;
Yonghua ZHAO
;
Bingzhu YAN
;
Shuchen LI
- Publication Type:Journal Article
- Keywords:
Hepatitis C,chronic;
Insulin resistance;
Metformin;
Polyethylene glycols;
Ribavirin
- From:
Chinese Journal of Infectious Diseases
2012;30(4):215-220
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the effect of adding metformin to peginterferon alfa-2a and ribavirin on the efficacy in patients with genotype 1 chronic hepatitis C and insulin resistance.Methods Ninety-eight patients with genotype 1 chronic hepatitis C and insulin resistance were randomized into the treatment group (n=49) and the control group (n=49).The patients in the control group were treated with peginterferon alfa-2a and ribavirin,and those in the treatment group were treated with metformin in addition to peginterferon alfa-2a and ribavirin. The virologic response rate,the homeostasis model assessment for insulin resistence index (HOMA-IR) and incidence of side effects were compared between two groups.The related factors of sustained virological response (SVR) were studied by multivariate logistic regression analysis.ResultsThe SVR rate of the patients in the treatment group was significantly higher than that of the control group (59.2％ vs 38.8％; x2 =4.083,P=0.043).The HOMA-IR of patients in the treatment group at week 12,24,48 of treatment and week 24 of follow-up were 3.00±0.65,1.90±0.45,1.75±0.40 and 1.60±0.35,respectively,which were all lower than those in the control group (3.50±0.72,2.90±0.64,2.74± 0.48 and 2.60±0.55,respectively) (t=3.610,8.947,11.091 and 10.738,respectively; all P＜ 0.01).The incidence of diarrhea in the treatment group was higher than the control group (28.6％ vs 10.2％ ; x2 =5.288,P=0.021).In multivariate logistic regression analysis,the independent factors associated with SVR were metformin treatment (P =0.009) and HOMA-IR＜ 2 at week 24 of treatment (P=0.011 ). Conclusion The combination of metformin,peginterferon alfa-2a and ribavirin improves insulin sensitivity and increases SVR rate of patients with hepatitis C genotype 1 and insulin resistance with good safety profile.
